Related Experiment Videos
Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease
R G Casey1, M Joyce, G Roche-Nagle
1Department of Surgical Research, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. rcasey@oceanfree.net
Background:
Development of diabetes causes early functional (endothelial dysfunction) and morphological abnormalities in the kidney. If left untreated, these will ultimately progress to renal failure. Apart from strategies aimed at maintaining very tight glycemic control, attention has turned to the development of adjuvant therapy to maintain endothelial function in these patients. The agents receiving the most critical appraisal due to their endothelial protective effects are the 3-hydrox 3-methylglutaryl (HMG)-Co-enzyme A (CoA) reductase inhibitors. The aim of the study was to investigate: (1) the early alterations in the renal diabetic injury; and (2) to examine the protective role of Pravastatin in this end-organ diabetic model.
Materials And Methods:
Sprague Dawley rats (n = 21) were randomized into three groups: (1) control; (2) diabetic; and (3) diabetic treated with Pravastatin. Diabetic nephropathy was investigated with serum biochemical parameters (urea, creatinine), functional parameters (total urinary protein loss, glomerular filtration rate, renal cortical blood flow), and structural assessment (hemotoxylin and eosin staining).
Results:
We demonstrated impairment in functional, biochemical, and structural parameters in the diabetic nephropathy group, which was diminished by treatment with Pravastatin. This was attributed to an up-regulation in endothelial constitutive nitric oxide synthase (ecNOS) expression in the treated diabetic group.
Conclusions:
We have shown that Pravastatin, in an experimental model of early diabetes nephropathy preserves microvascular endothelial function in the presence of hyperglycemia, thus inhibiting the early stage of diabetic microangiopathy.
Insights
Pravastatin treatment in diabetic rats mitigated kidney damage by preserving endothelial function and up-regulating nitric oxide synthase. This study highlights Pravastatin
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus causes early kidney abnormalities, including endothelial dysfunction, potentially leading to renal failure.
- Statins, specifically 3-hydroxy-3-methylglutaryl (HMG)-Coenzyme A (CoA) reductase inhibitors, are investigated for their endothelial protective effects.
- Adjuvant therapies are explored to maintain endothelial function in diabetic patients alongside glycemic control.
Purpose of the Study:
- To investigate early alterations in renal injury associated with diabetes.
- To examine the protective role of Pravastatin in an experimental model of diabetic nephropathy.
Main Methods:
- Sprague Dawley rats were divided into control, diabetic, and diabetic treated with Pravastatin groups.
- Diabetic nephropathy was assessed using serum biochemical markers (urea, creatinine), functional parameters (urinary protein, GFR, renal cortical blood flow), and structural analysis (H&E staining).
- Endothelial constitutive nitric oxide synthase (ecNOS) expression was evaluated.
Main Results:
- Diabetic nephropathy induced impairments in functional, biochemical, and structural kidney parameters.
- Pravastatin treatment significantly diminished these impairments in diabetic rats.
- This protective effect was associated with an up-regulation of ecNOS expression in the Pravastatin-treated diabetic group.
Conclusions:
- Pravastatin preserves microvascular endothelial function in an experimental model of early diabetic nephropathy.
- The findings suggest Pravastatin inhibits the early stages of diabetic microangiopathy, even under hyperglycemic conditions.
- Pravastatin demonstrates potential as a therapeutic agent to protect the kidney in early diabetes.
